Mesothelioma Clinical Trials

A mesothelioma diagnosis is a serious one, but it is not one without hope. There are a variety of treatments available, and a number of ongoing clinical trails.

Trial Status

We do our best to keep the current status (closed, currently recruiting, upcoming) of each clinical trial up-to-date. Several clinical trials are listed at ClinicalTrials.gov as "currently recruiting" despite the estimated completion date having been long past. The contact for a particular clinical trial is your best bet to discover if a particular clinical trial is still open and recruiting.

Glossary

To help you as you read through these clinical trials, we have glossary of terms and their definitions. Words underlined with a dashed line are part of the glossary; to see their definition, simply click on the word.

Clinical Trials

Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53

Primary Outcome Measures Phase 1a: To assess safety and tolerability of ASTX295 including determination of maximum tolerated dose (MTD), and/or recommended dose for expansion (RDE) to Phase 1b. [ Time Frame: From the date of the first dose until 30 days after discontinuation of study treatment. ]The safety and tolerability will be based on Incidence ... [More >>]

Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers

Primary Outcome Measures Objective Response Rate (ORR) [ Time Frame: 24 months ] Number of patients with Complete Response (CR) + Number of patients with Partial Response (PR) / total number of patients (# with CR + # with PR + # with SD + # with PD), per RECIST v1.1: CR: Disappearance of all target ... [More >>]

APG-2449 in Patients With Advanced Solid Tumors

Primary Outcome Measures Maximum Tolerated Dose (MTD) [ Time Frame: 28 days ]To determine the maximum tolerated dose (MTD) of APG-2449 in subjects with advanced solid tumorsRecommended Phase 2 dose (RP2D) [ Time Frame: 28 days ]To determine the tentative recommended Phase 2 dose (RP2D) of APG-2449 in subjects with advanced solid tumors Secondary Outcome Measures Maximum plasma concentration (Cmax) [ Time Frame: 28 ... [More >>]

Phase 1/2 Trial of TC-210 T Cells in Patients With Advanced Mesothelin-Expressing Cancer

Primary Outcome Measures Phase 1 - Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ]Phase 2 - To evaluate the efficacy of autologous genetically modified TC-210 T cells in patients with MSLN-expressing unresectable, metastatic, or recurrent cancers as determined ... [More >>]

INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105)

Primary Outcome Measures Number of treatment-emergent adverse events with INCMGA00012 in combination with chemotherapy [ Time Frame: Up to approximately 27 months ]Adverse events reported for the first time or worsening of a pre-existing event after the first dose of study treatment. Secondary Outcome Measures Objective response rate (ORR) [ Time Frame: Through study completion, up to approximately 31 months ]Defined ... [More >>]

Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma

Primary Outcome Measures Safety Profile of neoadjuvant nivolumab +/- ipilimumab in patients with resectable malignant pleural mesothelioma (MPM) with grade III/IV adverse events defined by CTCAE v5.0 [ Time Frame: up to 5 years ]Number of participants with grade III/IV adverse events defined by CTCAE v5.0, occurring within 100 days of last study drug administration ... [More >>]

Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)

Primary Outcome Measures Overall survival [ Time Frame: from randomization of first patient until the database cut-off ]The overall survival is defined as the time from the date of randomization to the date of death from any cause Secondary Outcome Measures Response to treatment using PFS [ Time Frame: week 10, week21,every 4 months during 2 years ]Progression free survival (PFS) ... [More >>]

Magnetic Resonance Imaging for Detection of Peritoneal Mesothelioma

Primary Outcome Measures Higher Sensitivity for detection using New High Resolution Contrast Enhanced MRI Imaging Sequences compared to standard MRI [ Time Frame: 60 Days ]New HR-MRI sequences will demonstrate greater sensitivity than standard MRI for detecting peritoneal metastases.Higher sensitivity for detection of peritoneal metastatic disease using Ultrasound Elastography compared to standard MRI [ Time Frame: 60 Days ]Ultrasound ... [More >>]

A Study of CA-170 (Oral PD-L1, PD-L2 and VISTA Checkpoint Antagonist) in Patients With Advanced Tumors and Lymphomas

Primary Outcome Measures The number of patients with a dose-limiting toxicity (DLT) in the first treatment cycle [ Time Frame: Approximately 24 months ]Maximum tolerated dose (MTD) of CA-170 [ Time Frame: Approximately 24 months ]Recommended Phase 2 Dose (RP2D) of CA-170 [ Time Frame: Approximately 24 months ] Secondary Outcome Measures Pharmacokinetic (PK) Profile of CA-170 [ Time Frame: From Day 1 of Cycle 1(each cycle is 21 days) ]Maximum Concentration (Cmax)Pharmacokinetic (PK) Profile ... [More >>]

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

Primary Outcome Measures Initial efficacy of LUM015 in labeling peritoneal surface malignancies by molecular imaging by comparing imaging results with pathology [ Time Frame: 1 Day ] Correlate the fluorescence levels in tumor tissue imaging to the dose of LUM015 injected. Secondary Outcome Measures Number of patients with reported adverse events [ Time Frame: ... [More >>]

Last update: May 07, 2019. 08:38:48 pm.